Related Experiment Video
Updated: Jul 1, 2025
06:55
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.5K
Medication adherence in patients with type 2 diabetes after disability onset: a difference-in-differences analysis
Szu-Han Chen1, Miaw-Chwen Lee2,3,4, Christy Pu5
1Department of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
BMC Medicine
|March 6, 2024
Summary
Disability onset significantly reduces type 2 diabetes medication adherence, with greater impacts seen in specific disability types. This highlights the need for tailored support strategies for individuals managing both conditions.
Area of Science:
- Public Health
- Epidemiology
- Health Services Research
Background:
- Managing comorbid diabetes and disability presents significant challenges.
- The impact of disability onset on medication adherence in type 2 diabetes is not well understood.
- Investigating this relationship is crucial for effective patient management.
Purpose of the Study:
- To determine if disability onset affects adherence to type 2 diabetes medication.
- To analyze variations in adherence reduction based on disability type.
Main Methods:
- Utilized Taiwan's National Disability Registry and National Health Insurance Research Database (2013-2020).
- Matched type 2 diabetes patients with and without subsequent disability onset.
- Employed difference-in-differences analysis to assess medication possession ratio (MPR).
Main Results:
- Disability onset led to a 5.76% reduction in 1-year MPR (P < 0.001).
- A significant 13.21% decrease in 2-year MPR was observed (P < 0.001).
- Organ disabilities, multiple disabilities, rare diseases, and persistent vegetative states showed the largest adherence reductions.
Conclusions:
- Disability onset negatively impacts type 2 diabetes medication adherence.
- Adherence reduction varies substantially by disability type.
- Policies must address specific challenges faced by individuals with disabilities to improve medication adherence.
More Related Videos
Related Concept Videos
01:20Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
02:07Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
01:12Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
01:15Diabetes: Management and Pharmacotherapy
282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282
01:23Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K